52,500 Shares in Cellebrite DI Ltd. $CLBT Acquired by Cannon Global Investment Management LLC

Cannon Global Investment Management LLC purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 52,500 shares of the company’s stock, valued at approximately $723,000. Cellebrite DI accounts for about 1.4% of Cannon Global Investment Management LLC’s holdings, making the stock its 22nd largest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Voss Capital LP raised its stake in shares of Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after acquiring an additional 1,277,300 shares during the period. Pertento Partners LLP increased its holdings in Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares in the last quarter. Invesco Ltd. raised its position in Cellebrite DI by 0.8% in the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after purchasing an additional 43,041 shares during the period. Granahan Investment Management LLC lifted its stake in shares of Cellebrite DI by 16.3% during the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares in the last quarter. Finally, Cooper Creek Partners Management LLC purchased a new stake in shares of Cellebrite DI in the third quarter worth about $55,999,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $13.76 on Friday. The firm’s 50-day simple moving average is $13.21 and its 200-day simple moving average is $14.73. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98. The firm has a market cap of $3.43 billion, a PE ratio of 49.14, a price-to-earnings-growth ratio of 1.56 and a beta of 1.17.

Insider Activity

In related news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 13,269 shares of company stock worth $169,592. Corporate insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CLBT. DA Davidson assumed coverage on Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.